We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of hyperkalemia associated with intravenous co-trimoxazole in hospitalized patients in Oman.
- Authors
Abdalaziz, Dalia; Al-Zakwani, Ibrahim; Abdelrahman, Aly; Hamdy, Ibrahim; AlSuleimani, Yousuf
- Abstract
Co-trimoxazole is a combination of two antimicrobial drugs, (trimethoprim and sulfamethoxazole), that are used to treat a wide variety of infections such as urinary tract infection, pneumocystis pneumonia and traveler's diarrhea. Hyperkalemia is a life-threatening electrolyte disturbance. Objectives: This study aimed to determine the incidence of hyperkalemia and its risk factors among hospitalized patients receiving intravenous co-trimoxazole at Sultan Qaboos University Hospital (SQUH) in Muscat, Oman. Methods: This retrospective observational study included patients that were prescribed intravenous co-trimoxazole and identified using a computerized pharmacy system between January 2010 and December 2020. Patients' demographic and clinical characteristics were retrieved from their electronic medical records. The data were analyzed using descriptive and inferential statistical tests. Results: A total of 420 patients participated in this study. The median age of the patients was 51 (35-65) years and 55.5% were male. Hyperkalemia associated with co-trimoxazole was observed in (40.2%) of the patients. Around (44.2%) of patients who experienced hyperkalemia received a high dose of co-trimoxazole (15-20 mg/kg). Hyperkalemia occurred after the 5th day of co-trimoxazole treatment. Logistic regression analysis showed no relationship between hyperkalemia and age (adjusted odds ratio (AOR) 1.054, p=0.84), sex (AOR 1.167; p=0.471), dose (AOR 0.779; p=0.251), or use of concomitant medications (angiotensin-converting inhibitors, AOR 1.054, p=0.84; angiotensin receptor blockers, AOR 0.564; p=0.734; β-blockers, AOR 0.986; p=0.963; potassium supplements, AOR 0.59; p=0.175; nonsteroidal anti-inflammatory drugs, AOR 0.842, p=0.684; spironolactone AOR 0.748, p=0.629; heparin AOR 0.822, p=0.382; calcineurin inhibitor, AOR 1.537, p=0.406). Conclusion: Co-trimoxazole use was associated with a high incidence of hyperkalemia in this group of patients. No association between hyperkalemia and risk factors was observed. Serum potassium levels should be closely monitored, especially in the first week of co-trimoxazole treatment, to prevent the incidence of hyperkalemia, and clinical staff should adhere to serum monitoring guidelines.
- Subjects
OMAN; RISK assessment; NONSTEROIDAL anti-inflammatory agents; PHARMACEUTICAL arithmetic; SPIRONOLACTONE; HYPERKALEMIA; SCIENTIFIC observation; LOGISTIC regression analysis; SEX distribution; ACE inhibitors; POTASSIUM; HEPARIN; ENZYME inhibitors; RETROSPECTIVE studies; DESCRIPTIVE statistics; AGE distribution; INTRAVENOUS therapy; ANTI-infective agents; ODDS ratio; ANGIOTENSIN receptors; CO-trimoxazole; MEDICAL records; ACQUISITION of data; ELECTRONIC health records; INFERENTIAL statistics; PNEUMOCYSTIS pneumonia; ADRENERGIC beta blockers; PHARMACY databases; CONFIDENCE intervals; DISEASE risk factors
- Publication
Pharmacy Practice (1886-3655), 2024, Vol 22, Issue 3, p1
- ISSN
1885-642X
- Publication type
Article
- DOI
10.18549/PharmPract.2024.3.3004